LOC – Talk Bio

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

17 hours ago talkbio0Tagged Business Development, Cell Therapy, Galapagos, Gilead Sciences, GLPG5101, Mantle cell lymphoma, pipeline, Sales - occupational activity, strategic alternatives

Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development

FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot

1 month ago talkbio0Tagged Approved, Gilead Sciences, HIV Prevention, Lenacapavir, PREP gene, public health medicine (field), twice-yearly injection, United States Food and Drug Administration, Yeztugo

FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health

Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Bay Area, biotech industry, Dosage Forms, genentech, layoffs, Roche (company), South San Francisco, WARN filing

Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry

Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets

2 months ago talkbio0Tagged Appointments, Automobiles, biotech industry, Cell Therapy, CEO, Company Split, Galapagos, spinoff, T business

Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business

Galapagos Reconsiders Company Split After Market Developments

2 months ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

4 months ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

6 months ago talkbio0Tagged Antidote, CAR-T, Catalent, decentralized, Duodote, Galapagos, Kindeva, Lymphoma, Non-Hodgkin, Manufacturing, Nerve Agents, NHL, Strategic National Stockpile

Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile